These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
25. Update on the ECG component of the CiPA initiative. Vicente J J Electrocardiol; 2018; 51(6S):S98-S102. PubMed ID: 30121123 [TBL] [Abstract][Full Text] [Related]
26. Three-Dimensional Heart Model-Based Screening of Proarrhythmic Potential by Hwang M; Han S; Park MC; Leem CH; Shim EB; Yim DS Front Physiol; 2019; 10():1139. PubMed ID: 31551815 [TBL] [Abstract][Full Text] [Related]
27. A deep learning platform to assess drug proarrhythmia risk. Serrano R; Feyen DAM; Bruyneel AAN; Hnatiuk AP; Vu MM; Amatya PL; Perea-Gil I; Prado M; Seeger T; Wu JC; Karakikes I; Mercola M Cell Stem Cell; 2023 Jan; 30(1):86-95.e4. PubMed ID: 36563695 [TBL] [Abstract][Full Text] [Related]
28. Assessment of the proarrhythmic potential of the novel antiarrhythmic agent AZD7009 and dofetilide in experimental models of torsades de pointes. Wu Y; Carlsson L; Liu T; Kowey PR; Yan GX J Cardiovasc Electrophysiol; 2005 Aug; 16(8):898-904. PubMed ID: 16101634 [TBL] [Abstract][Full Text] [Related]
29. Statistical learning in preclinical drug proarrhythmic assessment. Xi NM; Hsu YY; Dang Q; Huang DP J Biopharm Stat; 2022 May; 32(3):450-473. PubMed ID: 35771997 [TBL] [Abstract][Full Text] [Related]
30. Introduction to Park JS; Jeon JY; Yang JH; Kim MG Transl Clin Pharmacol; 2019 Mar; 27(1):12-18. PubMed ID: 32055576 [TBL] [Abstract][Full Text] [Related]
31. A rabbit Langendorff heart proarrhythmia model: predictive value for clinical identification of Torsades de Pointes. Lawrence CL; Bridgland-Taylor MH; Pollard CE; Hammond TG; Valentin JP Br J Pharmacol; 2006 Dec; 149(7):845-60. PubMed ID: 17031389 [TBL] [Abstract][Full Text] [Related]
32. Detection of Drug-Induced Torsades de Pointes Arrhythmia Mechanisms Using hiPSC-CM Syncytial Monolayers in a High-Throughput Screening Voltage Sensitive Dye Assay. da Rocha AM; Creech J; Thonn E; Mironov S; Herron TJ Toxicol Sci; 2020 Feb; 173(2):402-415. PubMed ID: 31764978 [TBL] [Abstract][Full Text] [Related]
33. Assessment of efficacy of proarrhythmia biomarkers in isolated rabbit hearts with attenuated repolarization reserve. Orosz S; Sarusi A; Csík N; Papp JG; Varró A; Farkas S; Forster T; Farkas AS; Farkas A J Cardiovasc Pharmacol; 2014 Sep; 64(3):266-76. PubMed ID: 24887684 [TBL] [Abstract][Full Text] [Related]
34. A new biomarker--index of cardiac electrophysiological balance (iCEB)--plays an important role in drug-induced cardiac arrhythmias: beyond QT-prolongation and Torsades de Pointes (TdPs). Lu HR; Yan GX; Gallacher DJ J Pharmacol Toxicol Methods; 2013; 68(2):250-259. PubMed ID: 23337247 [TBL] [Abstract][Full Text] [Related]
35. Occurrence of early afterdepolarization under healthy or hypertrophic cardiomyopathy conditions in the human ventricular endocardial myocyte: In silico study using 109 torsadogenic or non-torsadogenic compounds. Christophe B Toxicol Appl Pharmacol; 2022 Mar; 438():115914. PubMed ID: 35150662 [TBL] [Abstract][Full Text] [Related]
37. Sensitive and reliable proarrhythmia in vivo animal models for predicting drug-induced torsades de pointes in patients with remodelled hearts. Sugiyama A Br J Pharmacol; 2008 Aug; 154(7):1528-37. PubMed ID: 18552873 [TBL] [Abstract][Full Text] [Related]